Year 2016 Vol. 24 No 4

SCIENTIFIC PUBLICATIONS
EXPERIMENTAL SURGERY

A.O. BAIYRKHANOVA1, T.K. BOTABEKOVA2, Y.M. SEMENOVA1

THE STUDY OF ANTI-PROLIFERATIVE EFFECT OF INTRAVITREAL IMPLANT IN SURGICAL TREATMENT OF PROLIFERATIVE VITREORETINOPATHY

Semey State Medical University1, Semey
JSC "Scientific Research Institute of Eye Diseases of the Badge of Honor Order"2 of Kazakhstan, Almaty
The Republic of Kazakhstan

Objectives. To study the anti-proliferative effect of chitosan film (ChF) in surgical treatment of experimental proliferative vitreoretinopathy (PVR) by the ultrasound method (US).
Methods. This study has been conducted on 10 adult rabbits (20 eyes) of “chinchilla” breed weighing 2,5 – 4,0 kg. To develop an experimental PVR the autohemotherapy (0,4 ml) is used. The eyes of animals were divided into 4 groups: the 1st and 2nd – the main groups – 10 right eyes (5 eyes – the implantation of ChF saturated with 5-fluorouracil (5-FU) and 5 eyes – ChF without 5-FU), the 1st and 2nd control groups – 10 left eyes (without implanting the film). On the 10th and 31st days after operation the anti-proliferative effect has been com­pared.
Results. On the 10th day the partial hemophthalmos in 4 eyes of the 1st and 2nd main groups and in all eyes of control groups has been noted. There was a vitreoretinal cord in the posterior part in 4 eyes of the 1st and 2nd control groups. On the 31st day in 2 eyes of the 1st main group tur­bid­ity of a vitreous body was observed. In 1 eye of the Ist main group and 3 eyes of the 2nd main group the partial hemophthalmos was noted. A vitreoretinal cord was visualized in 3 eyes of the 2nd main group. In all eyes of the control groups a hemophthalmos in the forming stage was observed, and the posterior covers were thickened. There was a vitreoretinal cord in 4 eyes of the 1st control and in 5 eyes of the 2nd control groups, the whole vitreous body was filled with accurate contours shadows; the exudate – in the posterior part.
Conclusion. Using the chitosan film with 5-fluorouracil enhances the anti-proliferative effect to a great extent. The chitosan film without 5-fluorouracil also blocks the proliferation process, but to a lesser extent. After the morphological studies the given implant can be clinically applied during vitreous surgery to prevent recurrence in the incisional period.

Keywords: vitreous body, proliferative vitreoretinopathy, chitosan, 5-fluorouracil, morphological studies, vitreous surgery, incisional period
p. 336-341 of the original issue
References
  1. Sosnovskii SV, Boiko EV, Kharitonova NN. Obosnovanie i razra¬botka sistemy kolichestvennoi otsenki tiazhesti proliferativnoi vitreoretinopatii [Justification and development of a quantitative estimation of severity of proliferative vitreoretinopathy]. Oftal'mokhirurgiia. 2009;(4):25-30.
  2. Kochmala OB, Zapuskalov IV, Krivosheina OI, Dashko IA. Khirurgiia otsloiki setchatki: sovremennoe sostoianie problemy [Retinal detachment surgery: state of the problem]. Vestn Oftal'mologii. 2010;(6):46-49.
  3. Goezinne F, La Heij EC, Berendschot TT, Kessels AG, Liem AT, Diederen RM, et al. Incidence of redetachment 6 months after scleral buckling surgery. Acta Ophthalmol. 2010 Mar;88(2):199-206. doi: 10.1111/j.1755-3768.2008.01425.x.
  4. Heimann H, Zou X, Jandeck C, Kellner U, Bechrakis NE, Kreusel KM, et al. Primary vitrectomy for rhegmatogenous retinal detachment: an analysis of 512 cases. Graefes Arch Clin Exp Ophthalmol. 2006 Jan;244(1):69-78.
  5. Salicone A, Smiddy WE, Venkatraman A, Feuer W. Management of retinal detachment when no break is found. Ophthalmology. 2006 Mar;113(3):398-403.
  6. Foster RE, Meyers SM. Recurrent retinal detachment more than 1 year after reattachment. Ophthalmology. 2002 Oct;109(10):1821-27.
  7. Miki D, Hida T, Hotta K, Shinoda K, Hirakata A. Comparison of scleral buckling and vitrectomy for retinal detachment resulting from flap tears in superior quadrants. Jpn J Ophthalmol. 2001 Mar-Apr;45(2):187-91.
  8. Sharma YR, Karunanithi S, Azad RV, Vohra R, Pal N, Singh DV, et al. Functional and anatomic outcome of scleral buckling versus primary vitrectomy in pseudophakic retinal detachment. Acta Ophthalmol Scand. 2005 Jun;83(3):293-97.
  9. Zakharov VD, Sharipova DN, Shatskikh AV, Novikov SV, Leont'eva GD. Sposob kombinirovannogo lecheniia eksperimental'noi PVR s primeneniem 5-ftoruratsila na gidrogelevom nositele [The method of combined treatment of experimental proliferative vitreoretinopathy with 5-fluorouracil on the hydrogel carrier]. Oftal'mokhirurgiia. 2006;(3):25-29.
  10. Lazarenko VI, Bol'shakov IN, Il'enkov SS, Shatilova RI, Kuzovnikov VV, Chanchikov DG, dr. Opyt primeneniia izdelii meditsinskogo naznacheniia Bol-khit i Kollakhit-bol» v oftal'mologii [Experience of the application of medical devices "Balll-chit" and "Kollachit-ball" in ophthalmology]. Ros Oftal'mol Zhurn. 2009;2(4):21-24.
  11. Yang H, Wang R, Gu Q, Zhang X. Feasibility study of chitosan asintravitreous tamponade material. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8):1095-97. doi: 10.1007/s00417-008-0813-8.
  12. Botabekova TK, Baiyrkhanova AO, Enin EA, Semenova IuM, Kampik A. Izuchenie sostoianiia vnutriglaznykh struktur posle intravitreal'nogo vvedeniia khitozanovoi plenki, nasyshchennoi 5-ftoruratsilom v eksperimente [The experimental study of the intraocular structures after intravitreal injection of chitosan film saturated with 5-fluorouracil]. Nauka i Zdravookhranenie. 2015;(6):133-46.
  13. Baiyrkhanova A, Ismailova A, Botabekova T, Enin E, Semenova Y. Crosslinked Chitosan/PVA film, suturated with 5- Fluorouracil for the prevention of proliferative vitreoretinopathy. Int J Drug Deliv Tech. 2016 Apr-Jun;6(2):47-51.
  14. Nassar K, Lüke J, Lüke M, Kamal M, Soliman MM, Grisanti S, et al. Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy. Int J Exp Pathol. 2015 Apr;96(2):103-10. doi: 10.1111/iep.12119.
  15. Berger AS, Cheng CK, Pearson PA, Ashton P, Crooks PA, Cynkowski T, et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2318-25.
  16. Hou H, Nieto A, Ma F, Freeman WR, Sailor MJ, Cheng L. Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon. J Control Release. 2014 Mar 28;178:46-54. doi: 10.1016/j.jconrel.2014.01.003.
Address for correspondence:
071400, Republic of Kazakhstan, Semey, Abay str.,103, office 141,
State Medical University.
Tel: 8701720 30 42
E-mail: alma23021984@gmail.com
Information about the authors:
Baiyrkhanova A.O. Applicant for Doctor’s degree, Semey State Medical University.
Botabekova T.K. Corresponding member, NAS of the Republic of Kazakhstan, MD, Professor, JSC "Scientific Research Institute of Eye Diseases of the Badge of Honor Order"2 of Kazakhstan, Chairman of the Board, Almaty.
Semenova Y.M. PhD, Head teacher, chair of ophthalmology, Ass. Professor, chair of general surgery, Semey State Medical University.
Contacts | ©Vitebsk State Medical University, 2007-2023